Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Milo Gatti

Showing results (41-50 of 168) with videos related to

Pageof 17
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 17, 2026
Comparison of ceftolozane-tazobactam and ceftazidime-avibactam in the treatment of MDR/DTR Pseudomonas aeruginosa infections: a systematic review and meta-analysisMilo Gatti, Riccardo De Paola, Beatrice Giorgi, et al.
International Journal of Antimicrobial Agents|April 6, 2024
In reply to the Letter to the Editor regarding "Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis"Milo Gatti, Federica Cosentino, Maddalena Giannella, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety IssuesMilo Gatti, Eleonora Turrini, Emanuel Raschi, et al.
Drug Design, Development and Therapy|August 11, 2021
Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the GapNicolina Conti, Milo Gatti, Emanuel Raschi, et al.
Therapeutic Drug Monitoring|August 8, 2024
Development and Validation of a Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Ceftolozane and Tazobactam in Human Plasma MicrosamplesMatteo Conti, Beatrice Giorgi, Milo Gatti, et al.
British Journal of Clinical Pharmacology|November 7, 2022
Clinical efficacy of renal dosing adjustments of ceftazidime-avibactam in patients affected by carbapenem-resistant Gram-negative infections: A systematic review and meta-analysis of observational studiesMilo Gatti, Giacomo Fornaro, Pierluigi Viale, et al.
Microorganisms|January 25, 2025
Usefulness of a TDM-Guided Approach for Optimizing Teicoplanin Exposure in the Treatment of Secondary Bloodstream Infections Caused by Glycopeptide-Susceptible <i>Enterococcus faecium</i>Milo Gatti, Matteo Rinaldi, Maddalena Giannella, et al.
Molecules (Basel, Switzerland)|July 13, 2024
Colistin: Lights and Shadows of an Older AntibioticErica Diani, Gabriele Bianco, Milo Gatti, et al.
Expert Opinion on Drug Metabolism & Toxicology|September 6, 2023
Pharmacokinetic and pharmacodynamic considerations for optimizing antimicrobial therapy used to treat bone and joint infections: an evidence-based algorithmic approachMilo Gatti, Sara Tedeschi, Eleonora Zamparini, et al.
International Journal of Antimicrobial Agents|December 7, 2023
Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysisMilo Gatti, Federica Cosentino, Maddalena Giannella, et al.
Pageof 17

Showing results (41-50 of 168) with videos related to

Sort By:
Pageof 17
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 17, 2026
Comparison of ceftolozane-tazobactam and ceftazidime-avibactam in the treatment of MDR/DTR Pseudomonas aeruginosa infections: a systematic review and meta-analysisMilo Gatti, Riccardo De Paola, Beatrice Giorgi, et al.
International Journal of Antimicrobial Agents|April 6, 2024
In reply to the Letter to the Editor regarding "Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis"Milo Gatti, Federica Cosentino, Maddalena Giannella, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety IssuesMilo Gatti, Eleonora Turrini, Emanuel Raschi, et al.
Drug Design, Development and Therapy|August 11, 2021
Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the GapNicolina Conti, Milo Gatti, Emanuel Raschi, et al.
Therapeutic Drug Monitoring|August 8, 2024
Development and Validation of a Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Ceftolozane and Tazobactam in Human Plasma MicrosamplesMatteo Conti, Beatrice Giorgi, Milo Gatti, et al.
British Journal of Clinical Pharmacology|November 7, 2022
Clinical efficacy of renal dosing adjustments of ceftazidime-avibactam in patients affected by carbapenem-resistant Gram-negative infections: A systematic review and meta-analysis of observational studiesMilo Gatti, Giacomo Fornaro, Pierluigi Viale, et al.
Microorganisms|January 25, 2025
Usefulness of a TDM-Guided Approach for Optimizing Teicoplanin Exposure in the Treatment of Secondary Bloodstream Infections Caused by Glycopeptide-Susceptible <i>Enterococcus faecium</i>Milo Gatti, Matteo Rinaldi, Maddalena Giannella, et al.
Molecules (Basel, Switzerland)|July 13, 2024
Colistin: Lights and Shadows of an Older AntibioticErica Diani, Gabriele Bianco, Milo Gatti, et al.
Expert Opinion on Drug Metabolism & Toxicology|September 6, 2023
Pharmacokinetic and pharmacodynamic considerations for optimizing antimicrobial therapy used to treat bone and joint infections: an evidence-based algorithmic approachMilo Gatti, Sara Tedeschi, Eleonora Zamparini, et al.
International Journal of Antimicrobial Agents|December 7, 2023
Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysisMilo Gatti, Federica Cosentino, Maddalena Giannella, et al.
Pageof 17